Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2012-11-28 | Evotec (Germany) Probiodrug (Germany) | assays to support the pre-clinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer’s disease | Alzheimer’s disease | collaboration services |
Neurodegenerative diseases | |
2012-11-28 | Beactica (Sweden) Janssen Research & Development - J&J (Belgium-USA) | Sprint™ | undisclosed | R&D |
undisclosed | R&D agreement |
2012-11-28 | Sanofi (France) Selecta Biosciences (USA) | antigen-specific immunotherapies | life-threatening allergies | R&D |
Allergic diseases - Immunological diseases | R&D agreement |
2012-11-28 | Hovione (Portugal) Solvias (Switzerland) | pharmaceutical co-crystals | collaboration |
Collaboration agreement | ||
2012-11-27 | Mundipharma (UK) Northlake International (USA) Hangzhou Minsheng Pharmaceutical (China) | NL-101 and back-up molecules | haematological malignancies | R&D |
Cancer - Oncology | R&D agreement |
2012-11-23 | UCB (Belgium) Exemed Pharmaceuticals (India) | manufacturing |
Production agreement | |||
2012-11-23 | Orphan Europe, part of Recordati Group (Italy) Erytech (France) | Graspa® (L-asparaginase encapsulated in red blood cells, using technology owned by Erytech Pharma) | acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) | licensing |
Cancer - Oncology | Licensing agreement |
2012-11-22 | Activiomics (UK) Kyowa Hakko Kirin (Japan) | TIQUAS (Targeted In-depth QUAntification of cell Signaling) phosphoproteomics platform | R&D |
R&D agreement | ||
2012-11-22 | In-Cell-Art (France) Delta-Vir (Germany) | In-Cell-Art ICANtibodies™ technology | collaboration |
Cancer - Oncology | Collaboration agreement | |
2012-11-21 | Ablynx (Belgium) Algeta (Norway) | alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies® | R&D |
Cancer - Oncology | R&D agreement | |
2012-11-20 | Shire (UK) Boston Children’s Hospital (USA) | undisclosed rare pediatric diseases with high unmet medical need | R&D |
Rare diseases | R&D agreement | |
2012-11-19 | Bavarian Nordic (Denmark) U.S. Department of Homeland Security (DHS - USA) Science and Technology Directorate - National Institutes of Health (NIH - USA) | recombinant Modified Vaccinia virus Ankara (MVA)-based vaccines including MVA-BN®-based human vaccine against the viral hemorrhagic fever Marburg and MVA-BN®-based animal vaccine against Foot-and-mouth disease | viral hemorrhagic fever Marburg, Foot-and-mouth disease | development |
Infectious diseases | Development agreement |
2012-11-15 | bioMérieux (France) Quanterix (USA) | Simoa (Single MOlecule Array) technology | Simoa™ technology (named for single molecule array) is based upon the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents. This digital approach enables detection of a signal from single molecules of a labelled analyte, and is much more sensitive than conventional analog-based protein detection technologies. The main difference between Simoa and conventional immunoassays lies in the ability to trap single molecules in femtoliter-sized wells, allowing for a “digital” readout of each individual bead to determine if it is bound to the target analyte or not. The digital nature of the technique allows an average of 1000x sensitivity increase over conventional assays with CVs <10%. |
licensing |
Licensing agreement | |
2012-11-14 | biOasis Technologies (Canada) MedImmune (USA - global biologics arm of AstraZeneca (UK) | Transcend technology | Transcend technology is based on p97 (melanotransferrin). p97 can be used to deliver therapeutics agents through the Blood Brain Barrier (BBB). Brain capillaries, that comprise the BBB, possess an endogenous receptor that ferries an iron-transport protein, termed p97 (melanotransferrin), across the BBB. | R&D |
R&D agreement | |
2012-11-14 | GSK (UK) Alacris Theranostics (Germany) | ModCell™ System | R&D |
Cancer - Oncology | R&D agreement | |
2012-11-13 | Transgene (France) EORTC (EU) | TG4001 | HPV16 positive oropharyngeal squamous cell carcinoma | clinical research |
Cancer - Oncology | Clinical research agreement |
2012-11-13 | Vivalis (France) undisclosed partner | EB66® cell line | licensing |
Cancer - Oncology | Licensing agreement | |
2012-11-13 | Tigenix (Belgium) Genpharm Services (Dubai - United Arab Emirates) | ChondroCelect® | symptomatic cartilage defects of the knee | commercialisation |
Bone diseases | Commercialisation agreement |
2012-11-13 | Aptuit (USA) GSK (UK) | R&D |
R&D agreement | |||
2012-11-13 | Catalent Pharma Solutions (USA) Cevec Pharmaceuticals (Germany) | recombinant human alpha-1 antitrypsin (hAAT) - CAP® cell line - GPEx® technology | development |
Development agreement |